Organon cuts outlook despite Q3 beat amid JADA divestment
Source: SeekingAlpha
2025-11-10 08:55:55 ET
More on Organon
- Organon: Critical Assessment Of The Audit Committee Investigation Results
- The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products
- Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy
- Organon Non-GAAP EPS of $1.01 beats by $0.08, revenue of $1.6B beats by $20M
- Organon Q3 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Organon cuts outlook despite Q3 beat amid JADA divestment
Organon & Co.
NASDAQ: OGN
OGN Trading
-1.79% G/L:
$6.325 Last:
731,711 Volume:
$6.37 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
